Mirum Pharmaceuticals ((MIRM)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Mirum Pharmaceuticals is conducting a study titled ‘A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Biliary Cholangitis.’ The study aims to assess the effectiveness and safety of the investigational drug volixibat for treating itching associated with Primary Biliary Cholangitis (PBC) and its potential impact on disease progression.
The intervention being tested is volixibat, an oral Ileal Bile Acid Transporter (IBAT) inhibitor, administered in capsule form twice daily. The study includes different dosages of volixibat and a placebo for comparison.
This interventional study is randomized and follows a parallel assignment model with double masking for participants and investigators. Its primary purpose is treatment-focused, aiming to provide insights into volixibat’s efficacy and safety.
The study began on September 22, 2021, and is currently recruiting participants. The last update was submitted on August 21, 2025. These dates are crucial as they indicate the study’s progress and timeline for potential results.
The outcome of this study could significantly influence Mirum Pharmaceuticals’ stock performance and investor sentiment, especially if volixibat proves effective. It could also impact the competitive landscape in treatments for PBC-related pruritus.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.